CTOs on the Move

Cambrex

www.cambrex.com

 
Cambrex is the leading small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. Enjoy working with our experts to accelerate your small molecule therapeutics into the market.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.cambrex.com
  • 1 Meadowlands Plaza # 1510
    East Rutherford, NJ USA 07073
  • Phone: 201.804.3000

Executives

Name Title Contact Details

Similar Companies

HealthEconomics.Com

HealthEconomics.Com is the worlds most comprehensive and credible website for resources and jobs in healthcare value and market access.

Cychem

Cychem, Inc. is a Westlake Village, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shoppers Drug Mart

Built on a foundation of professional expertise and personal service, Shoppers Drug Mart has been meeting Canadians` health care needs for 50 years. What was once a small pharmacy in Toronto has grown into an organization of over 1,200 stores from coast to coast, becoming an indelible part of the lives of Canadians, young and old. Yet despite our growth, we have never forgotten our origins. We have always remained true to our belief that the personal satisfaction of each and every customer is at the root of our success - and it can only be ensured by the commitment of people who realize that success is built one customer at a time.

Artios Pharma

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.

Insertec

Insertec is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.